Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
GERN's Cash to Debt is ranked higher than
99% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. GERN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GERN' s 10-Year Cash to Debt Range
Min: 0.87  Med: 69.84 Max: No Debt
Current: No Debt
Equity to Asset 0.76
GERN's Equity to Asset is ranked higher than
59% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GERN: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
GERN' s 10-Year Equity to Asset Range
Min: 0.37  Med: 0.90 Max: 0.97
Current: 0.76
0.37
0.97
F-Score: 4
Z-Score: 1.52
M-Score: -5.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3045.81
GERN's Operating margin (%) is ranked lower than
85% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. GERN: -3045.81 )
Ranked among companies with meaningful Operating margin (%) only.
GERN' s 10-Year Operating margin (%) Range
Min: -41916.67  Med: -2520.37 Max: -149.32
Current: -3045.81
-41916.67
-149.32
Net-margin (%) -3005.35
GERN's Net-margin (%) is ranked lower than
86% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. GERN: -3005.35 )
Ranked among companies with meaningful Net-margin (%) only.
GERN' s 10-Year Net-margin (%) Range
Min: -41504.17  Med: -2377.67 Max: -131.51
Current: -3005.35
-41504.17
-131.51
ROE (%) -26.54
GERN's ROE (%) is ranked higher than
52% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. GERN: -26.54 )
Ranked among companies with meaningful ROE (%) only.
GERN' s 10-Year ROE (%) Range
Min: -157.63  Med: -48.36 Max: -17.94
Current: -26.54
-157.63
-17.94
ROA (%) -23.21
GERN's ROA (%) is ranked higher than
52% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. GERN: -23.21 )
Ranked among companies with meaningful ROA (%) only.
GERN' s 10-Year ROA (%) Range
Min: -85.77  Med: -39.69 Max: -14.86
Current: -23.21
-85.77
-14.86
ROC (Joel Greenblatt) (%) -33506.43
GERN's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. GERN: -33506.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GERN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -26858.87  Med: -1636.15 Max: -89.68
Current: -33506.43
-26858.87
-89.68
Revenue Growth (3Y)(%) -20.60
GERN's Revenue Growth (3Y)(%) is ranked lower than
68% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. GERN: -20.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GERN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -36.15 Max: 58.7
Current: -20.6
0
58.7
EBITDA Growth (3Y)(%) -32.90
GERN's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. GERN: -32.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GERN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -35.5  Med: -4.60 Max: 13.5
Current: -32.9
-35.5
13.5
EPS Growth (3Y)(%) -33.40
GERN's EPS Growth (3Y)(%) is ranked lower than
80% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. GERN: -33.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GERN' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.9  Med: -7.30 Max: 32.5
Current: -33.4
-35.9
32.5
» GERN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GERN Guru Trades in Q2 2014

First Eagle Investment 3,548,124 sh (+16.17%)
John Burbank 25,000 sh (unchged)
» More
Q3 2014

GERN Guru Trades in Q3 2014

John Burbank 25,000 sh (unchged)
First Eagle Investment 2,198,124 sh (-38.05%)
» More
Q4 2014

GERN Guru Trades in Q4 2014

Jim Simons 429,880 sh (New)
Paul Tudor Jones 15,072 sh (New)
John Burbank Sold Out
First Eagle Investment 1,128,866 sh (-48.64%)
» More
Q1 2015

GERN Guru Trades in Q1 2015

Paul Tudor Jones 71,723 sh (+375.87%)
Jim Simons 1,435,145 sh (+233.85%)
First Eagle Investment 728,866 sh (-35.43%)
» More
» Details

Insider Trades

Latest Guru Trades with GERN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.10
GERN's P/B is ranked lower than
54% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. GERN: 5.10 )
Ranked among companies with meaningful P/B only.
GERN' s 10-Year P/B Range
Min: 1.07  Med: 2.78 Max: 12.04
Current: 5.1
1.07
12.04
P/S 516.65
GERN's P/S is ranked lower than
180% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. GERN: 516.65 )
Ranked among companies with meaningful P/S only.
GERN' s 10-Year P/S Range
Min: 0  Med: 159.67 Max: 912.7
Current: 516.65
0
912.7
POCF 57.44
GERN's POCF is ranked lower than
68% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 35.29 vs. GERN: 57.44 )
Ranked among companies with meaningful POCF only.
GERN' s 10-Year POCF Range
Min: 0  Med: 0.00 Max: 62.88
Current: 57.44
0
62.88
EV-to-EBIT -13.44
GERN's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. GERN: -13.44 )
Ranked among companies with meaningful EV-to-EBIT only.
GERN' s 10-Year EV-to-EBIT Range
Min: -16.7  Med: -4.80 Max: -0.3
Current: -13.44
-16.7
-0.3
Current Ratio 3.64
GERN's Current Ratio is ranked lower than
55% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. GERN: 3.64 )
Ranked among companies with meaningful Current Ratio only.
GERN' s 10-Year Current Ratio Range
Min: 3.19  Med: 9.34 Max: 33.57
Current: 3.64
3.19
33.57
Quick Ratio 3.64
GERN's Quick Ratio is ranked lower than
53% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. GERN: 3.64 )
Ranked among companies with meaningful Quick Ratio only.
GERN' s 10-Year Quick Ratio Range
Min: 3.19  Med: 9.34 Max: 33.57
Current: 3.64
3.19
33.57
Days Sales Outstanding 357.20
GERN's Days Sales Outstanding is ranked lower than
95% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. GERN: 357.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
GERN' s 10-Year Days Sales Outstanding Range
Min: 26.84  Med: 141.23 Max: 6149.24
Current: 357.2
26.84
6149.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.97
GERN's Price/Net Cash is ranked higher than
61% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. GERN: 5.97 )
Ranked among companies with meaningful Price/Net Cash only.
GERN' s 10-Year Price/Net Cash Range
Min: 1.45  Med: 3.80 Max: 223.42
Current: 5.97
1.45
223.42
Price/Net Current Asset Value 5.88
GERN's Price/Net Current Asset Value is ranked higher than
58% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. GERN: 5.88 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GERN' s 10-Year Price/Net Current Asset Value Range
Min: 1.39  Med: 3.57 Max: 116.57
Current: 5.88
1.39
116.57
Price/Tangible Book 5.06
GERN's Price/Tangible Book is ranked higher than
54% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. GERN: 5.06 )
Ranked among companies with meaningful Price/Tangible Book only.
GERN' s 10-Year Price/Tangible Book Range
Min: 1.25  Med: 3.12 Max: 18.93
Current: 5.06
1.25
18.93
Earnings Yield (Greenblatt) (%) -7.39
GERN's Earnings Yield (Greenblatt) (%) is ranked lower than
58% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. GERN: -7.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GERN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -10.8  Med: 0.00 Max: 0
Current: -7.39
-10.8
0

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 2 2
EPS($) -0.24 -0.26
EPS without NRI($) -0.24 -0.26

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GON.Germany,
Geron Corp was incorporated in the State of Delaware on November 28, 1990. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in the segment of the discovery and development of therapeutic products for oncology. It owns worldwide commercial rights with U.S. patent coverage extending through 2025 for imetelstat. Its patent rights relating to telomerase cover the cloned genes that encode the RNA component and the catalytic protein component of human telomerase, cells that are immortalized by expression of recombinant hTERT, and cancer diagnostics based on detecting the expression of telomerase in cancer cells. The Company is subject to various and often changing federal, state, local and international laws, rules, regulations, guidelines and recommendations relating to safe working conditions and manufacturing practices.
» More Articles for GERN

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: HTM, OVTI, VSEA, KSWS,GERN, ATRC Jun 20 2011 
Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
Geron: Buyer Beware Oct 13 2010 
Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
Geron Corporation Reports 2009 Second Quarter Financial Results and Events Jul 30 2009 
Geron Corp (GERN): Stock of the Day Mar 10 2009 
Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
Can the Rally in Geron (GERN) Shares Continue? - Tale of the Tape Jun 24 2015
GERON CORP Files SEC form 8-K, Regulation FD Disclosure Jun 15 2015
Why Geron (GERN) Might Be a Diamond in the Rough - Tale of the Tape May 26 2015
GERON CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2015
Anne-Malorie Géron appointed as VP EU Affairs in Fortum's Corporate Relations May 21 2015
GERON CORP Financials May 15 2015
The Shuman Law Firm Investigates Geron Corp. May 11 2015
10-Q for Geron Corp. May 09 2015
GERON CORP Files SEC form 10-Q, Quarterly Report May 07 2015
10-K for Geron Corp. May 06 2015
Geron Q1 Loss In Line with Estimates, Restructuring on Track - Analyst Blog May 01 2015
Geron reports 1Q loss Apr 30 2015
Geron reports 1Q loss Apr 30 2015
Geron Corporation Reports First Quarter 2015 Financial Results and Recent Events Apr 30 2015
GERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 30 2015
Harwood Feffer LLP Announces Investigation of Geron Corporation Apr 29 2015
Geron Stock Alert: Schubert Firm Investigates Company's Top Executives Apr 28 2015
Geron to Present at the Bank of America Merrill Lynch Healthcare Conference Apr 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK